Insider · CIK 0001205703

CAGNONI PABLO J

Reports to the SEC for 7 companies · WILMINGTON, DE

sec.gov

Transactions

Companies

Filings

CIK

0001205703

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-15	INCYINCYTE CORPS Sale	President, Global Head of R&D	SSale	−9,233 sh	$120.50	−$1.11M	197,185
2026-09-15	INCYINCYTE CORPM Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	+4,551 sh	$61.18	+$278K	190,708
2026-09-15	INCYINCYTE CORP · Employee Stock Option (right to buy)M Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	−9,233 sh	—	—	18,466
2026-09-15	INCYINCYTE CORPM Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	+2,957 sh	$61.76	+$183K	186,157
2026-09-15	INCYINCYTE CORP · Employee Stock Option (right to buy)M Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	−2,957 sh	—	—	4,225
2026-09-15	INCYINCYTE CORP · Employee Stock Option (right to buy)M Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	−6,477 sh	—	—	20,356
2026-09-15	INCYINCYTE CORP · Employee Stock Option (right to buy)M Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	−4,551 sh	—	—	4,551
2026-09-15	INCYINCYTE CORPM Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	+6,477 sh	$64.25	+$416K	197,185
2026-09-15	INCYINCYTE CORPM Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	+9,233 sh	$71.93	+$664K	206,418
2026-09-15	INCYINCYTE CORPS Sale	President, Global Head of R&D	SSale	−14K sh	$120.49	−$1.69M	183,200
2026-08-19	INCYINCYTE CORPS Sale	President, Global Head of R&D	SSale	−10.8K sh	$125.56	−$1.36M	183,200
2026-08-12	INCYINCYTE CORPS Sale	President, Global Head of R&D	SSale	−10.8K sh	$120.04	−$1.3M	194,001
2026-08-05	INCYINCYTE CORPS Sale	President, Global Head of R&D	SSale	−10.6K sh	$122.69	−$1.31M	204,804
2026-07-31	INCYINCYTE CORPS Sale	President, Global Head of R&D	SSale	−15.9K sh	$119.70	−$1.9M	215,444
2026-07-16	INCYINCYTE CORPA Award	President, Global Head of R&D	AAward	+13.4K sh	—	—	231,332
2026-07-16	INCYINCYTE CORP · Performance SharesA Award	President, Global Head of R&D	AAward	+33.5K sh	—	—	33,508
2026-07-16	INCYINCYTE CORP · Employee Stock Option (right to buy)A Award	President, Global Head of R&D	AAward	+57.9K sh	—	—	57,861
2026-07-15	INCYINCYTE CORPF Tax Payment	President, Global Head of R&D	FTax Payment	−4,950 sh	$115.09	−$570K	217,929
2026-07-14	INCYINCYTE CORPF Tax Payment	President, Global Head of R&D	FTax Payment	−18K sh	$114.88	−$2.06M	222,879
2026-06-01	INCYINCYTE CORPF Tax Payment	President, Global Head of R&D	FTax Payment	−25.5K sh	$95.59	−$2.43M	240,848
2026-05-06	INCYINCYTE CORPA Award	President, Global Head of R&D	AAward	+31.5K sh	—	—	266,317
2026-04-17	INCYINCYTE CORPM Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	+12.6K sh	$71.93	+$906K	281,359
2026-04-17	INCYINCYTE CORP · Employee Stock Option (right to buy)M Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	−12.6K sh	—	—	27,699
2026-04-17	INCYINCYTE CORPM Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	+6,077 sh	$64.25	+$390K	268,769
2026-04-17	INCYINCYTE CORP · Employee Stock Option (right to buy)M Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	−6,077 sh	—	—	26,833
2026-04-17	INCYINCYTE CORPS Sale	President, Global Head of R&D	SSale	−18.7K sh	$96.50	−$1.8M	262,692
2026-04-15	INCYINCYTE CORPA Award	President, Global Head of R&D	AAward	+27.9K sh	—	—	262,692
2026-03-17	INCYINCYTE CORP · Employee Stock Option (right to buy)M Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	−7,166 sh	—	—	9,102
2026-03-17	INCYINCYTE CORPM Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	+11.5K sh	$64.25	+$739K	253,467
2026-03-17	INCYINCYTE CORP · Employee Stock Option (right to buy)M Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	−11.5K sh	—	—	32,910
2026-03-17	INCYINCYTE CORPM Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	+7,166 sh	$61.18	+$438K	241,966
2026-03-17	INCYINCYTE CORPS Sale	President, Global Head of R&D	SSale	−18.7K sh	$94.24	−$1.76M	234,800
2026-02-19	INCYINCYTE CORP · Employee Stock Option (right to buy)M Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	−13.1K sh	—	—	7,182
2026-02-19	INCYINCYTE CORP · Employee Stock Option (right to buy)M Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	−5,575 sh	—	—	16,268
2026-02-19	INCYINCYTE CORPS Sale	President, Global Head of R&D	SSale	−18.7K sh	$100.91	−$1.88M	234,800
2026-02-19	INCYINCYTE CORPM Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	+13.1K sh	$61.76	+$809K	247,893
2026-02-19	INCYINCYTE CORPM Exercise/Conversion	President, Global Head of R&D	MExercise/Conversion	+5,575 sh	$61.18	+$341K	253,468
2026-01-16	INCYINCYTE CORP · Employee Stock Option (right to buy)A Award	President, Global Head of R&D	AAward	+28.5K sh	—	—	28,475
2025-07-15	INCYINCYTE CORPA Award	President, Global Head of R&D	AAward	+17.5K sh	—	—	234,800
2025-07-15	INCYINCYTE CORPF Tax Payment	President, Global Head of R&D	FTax Payment	−2,628 sh	$68.25	−$179K	217,262
2025-07-15	INCYINCYTE CORP · Performance SharesA Award	President, Global Head of R&D	AAward	+43.8K sh	—	—	43,846
2025-07-15	INCYINCYTE CORP · Employee Stock Option (right to buy)A Award	President, Global Head of R&D	AAward	+39.5K sh	—	—	39,471
2025-07-14	INCYINCYTE CORPF Tax Payment	President, Global Head of R&D	FTax Payment	−1,280 sh	$69.98	−$89.6K	219,890
2025-01-17	INCYINCYTE CORP · Employee Stock Option (right to buy)A Award	President, Global Head of R&D	AAward	+40.3K sh	—	—	40,289
2024-07-15	INCYINCYTE CORP · Employee Stock Option (right to buy)A Award	President, Global Head of R&D	AAward	+44.4K sh	—	—	44,411
2024-07-15	INCYINCYTE CORPF Tax Payment	President, Global Head of R&D	FTax Payment	−749 sh	$64.25	−$48.1K	221,170
2024-07-15	INCYINCYTE CORPA Award	President, Global Head of R&D	AAward	+19.9K sh	—	—	221,919
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−141K sh	—	—	0
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17K sh	—	—	0
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17K sh	—	—	0

Recent filings

Accepted (ET)
Sep 174
CAGNONI PABLO J0001205703-26-000030
SEC(opens sec.gov)
Aug 204
CAGNONI PABLO J0001205703-26-000028
SEC(opens sec.gov)
Aug 144
CAGNONI PABLO J0001205703-26-000027
SEC(opens sec.gov)
Aug 74
CAGNONI PABLO J0001205703-26-000025
SEC(opens sec.gov)
Aug 44
CAGNONI PABLO J0001205703-26-000023
SEC(opens sec.gov)
Jul 204
CAGNONI PABLO J0001205703-26-000021
SEC(opens sec.gov)
Jul 164
CAGNONI PABLO J0001205703-26-000019
SEC(opens sec.gov)
Jun 34
CAGNONI PABLO J0001205703-26-000017
SEC(opens sec.gov)

Companies

Address

1801 AUGUSTINE CUT-OFF

WILMINGTON, DE, 19803